Cost of dupixent per year?

Dupixent (dupilumab) is a biologic drug used for atopic dermatitis, asthma, and chronic rhinosinusitis with nasal polyps. Its cost varies by country, payer, and insurance coverage, but here’s a quick snapshot of what most patients and payers see in the United States.

How the cost is determined

1. Drug price – Dupixent’s WAC is set by Regeneron and reflects the cost of biologic production, clinical development, and market positioning.
2. Insurance negotiation – Commercial plans often negotiate rebates or “real‑world” discounts. The “effective” cost to the payer can be 30‑40 % lower than WAC.
3. Patient assistance – Regeneron’s PAP or “Patient Support” programs can reduce or eliminate the copay for low‑income patients.
4. Out‑of‑pocket calculation – After the deductible, the plan’s coinsurance (often 20–30 %) is applied to the remaining drug cost.

What to expect if you’re covered

Tips to keep costs down

1. Check your formulary tier – Many plans put Dupixent on a higher tier with a higher copay; ask your provider or pharmacist if a lower‑tier alternative (e.g., tralokinumab or benralizumab) is possible.
2. Apply for the Regeneron PAP – If you meet the income criteria, this can cover the full cost.
3. Ask your prescriber for a “prior authorization” – They can sometimes secure a “preferred” brand name or negotiate a discount.
4. Consider a mail‑order pharmacy – Some plans give a 30‑day supply at a lower copay.

Bottom line: The manufacturer’s list price for Dupixent is roughly $27,000–$28,500 per year in the U.S., but most patients pay a fraction of that after insurance and/or patient‑assistance programs. If you’re looking for a precise estimate, it’s best to check with your insurer’s pharmacy benefits manager or call Regeneron’s Patient Support line.